抄録
Mesenchymal stromal cells (MSCs) derived from human bone marrow have capability to differentiate into cells of mesenchymal lineage. Especially, the differentiation capability towards osteogenic/chondrogenic cells is very well known. We have already used the patient's MSCs for the treatments of various patients who have osteoarthritis, bone necrosis and bone tumor. However, the proliferation and differentiation capability of the MSCs are variable and many cells lose their capabilities after several passages. With the aim of conferring higher capability on human bone marrow MSCs, we introduced the Sox2 gene into the cells and found that Sox2-expressing MSCs showed consistent proliferation and osteogenic capability in culture media containing basic fibroblast growth factor (bFGF) compared to control cells. We also found that Nanog-expressing cells even in the absence of bFGF had much higher capabilities for expansion and osteogenesis than control cells. Present paper describes our bone tissue engineering strategy and focuses on the importance of transcription factors for the function of MSCs.
